Hinokitiol is a novel glycoprotein VI antagonist on human platelets

Wan-Jung Lu, Ming Ping Wu, Kuan Hung Lin, Yu Chen Lin, Hsiu Chu Chou, Joen Rong Sheu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hinokitiol (4-isopropyl-tropolone) is a bioactive compound with various pharmacological activities that is found in the wood of cupressaceous plants. Platelet activation plays an important role in thrombogenesis. In our previous study, hinokitiol specifically inhibited collagen-induced platelet aggregation ex vivo and prolonged thrombogenesis in vivo. The glycoprotein (GP) VI and integrin α2β1 are major collagen receptors that mediate platelet adhesion and aggregation. In our current study, we investigated which of these collagen receptors is involved in the hinokitiol-mediated inhibition of platelet activation. Treatment with 2-100 μM hinokitiol caused a dose-dependent right, parallel shift in the collagen concentration-response curve (0.5-10 μg/ml), with no change in the maximal responses. Furthermore, hinokitiol inhibited platelet aggregation and relative [Ca2+]i mobilization stimulated by convulxin, an agonist of GP VI, but not by aggretin, an agonist of integrin α2β1, indicating that hinokitiol mediates the inhibition of platelet activation through GP VI, rather than through integrin α2β1. Hinokitiol also specifically inhibited the convulxin-mediated activation of protein kinase C, phospholipase Cγ2, Akt, mitogen-activated protein kinases, and Lyn. Hinokitiol markedly diminished the co-immunoprecipitation of GP VI-bound Lyn after convulxin stimulation. In conclusion, hinokitiol, an antagonist of collagen GP VI may represent a novel antiplatelet drug for the prevention of thrombi associated with coronary and cerebral artery diseases.

Original languageEnglish
Pages (from-to)595-602
Number of pages8
JournalPlatelets
Volume25
Issue number8
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Glycoproteins
Blood Platelets
Platelet Activation
Platelet Aggregation
Integrins
Collagen Receptors
Collagen
Cerebral Arterial Diseases
Tropolone
beta-thujaplicin
Phospholipases
Platelet Aggregation Inhibitors
Mitogen-Activated Protein Kinases
Immunoprecipitation
Protein Kinase C
Coronary Artery Disease
Thrombosis
Pharmacology
convulxin

Keywords

  • Collagen receptors
  • Convulxin
  • Glycoprotein VI
  • Hinokitiol
  • Platelet activation

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Hinokitiol is a novel glycoprotein VI antagonist on human platelets. / Lu, Wan-Jung; Wu, Ming Ping; Lin, Kuan Hung; Lin, Yu Chen; Chou, Hsiu Chu; Sheu, Joen Rong.

In: Platelets, Vol. 25, No. 8, 01.12.2014, p. 595-602.

Research output: Contribution to journalArticle

Lu, Wan-Jung ; Wu, Ming Ping ; Lin, Kuan Hung ; Lin, Yu Chen ; Chou, Hsiu Chu ; Sheu, Joen Rong. / Hinokitiol is a novel glycoprotein VI antagonist on human platelets. In: Platelets. 2014 ; Vol. 25, No. 8. pp. 595-602.
@article{b0dc99b513ee4c18a0d39613c1100dee,
title = "Hinokitiol is a novel glycoprotein VI antagonist on human platelets",
abstract = "Hinokitiol (4-isopropyl-tropolone) is a bioactive compound with various pharmacological activities that is found in the wood of cupressaceous plants. Platelet activation plays an important role in thrombogenesis. In our previous study, hinokitiol specifically inhibited collagen-induced platelet aggregation ex vivo and prolonged thrombogenesis in vivo. The glycoprotein (GP) VI and integrin α2β1 are major collagen receptors that mediate platelet adhesion and aggregation. In our current study, we investigated which of these collagen receptors is involved in the hinokitiol-mediated inhibition of platelet activation. Treatment with 2-100 μM hinokitiol caused a dose-dependent right, parallel shift in the collagen concentration-response curve (0.5-10 μg/ml), with no change in the maximal responses. Furthermore, hinokitiol inhibited platelet aggregation and relative [Ca2+]i mobilization stimulated by convulxin, an agonist of GP VI, but not by aggretin, an agonist of integrin α2β1, indicating that hinokitiol mediates the inhibition of platelet activation through GP VI, rather than through integrin α2β1. Hinokitiol also specifically inhibited the convulxin-mediated activation of protein kinase C, phospholipase Cγ2, Akt, mitogen-activated protein kinases, and Lyn. Hinokitiol markedly diminished the co-immunoprecipitation of GP VI-bound Lyn after convulxin stimulation. In conclusion, hinokitiol, an antagonist of collagen GP VI may represent a novel antiplatelet drug for the prevention of thrombi associated with coronary and cerebral artery diseases.",
keywords = "Collagen receptors, Convulxin, Glycoprotein VI, Hinokitiol, Platelet activation",
author = "Wan-Jung Lu and Wu, {Ming Ping} and Lin, {Kuan Hung} and Lin, {Yu Chen} and Chou, {Hsiu Chu} and Sheu, {Joen Rong}",
year = "2014",
month = "12",
day = "1",
doi = "10.3109/09537104.2013.863856",
language = "English",
volume = "25",
pages = "595--602",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Hinokitiol is a novel glycoprotein VI antagonist on human platelets

AU - Lu, Wan-Jung

AU - Wu, Ming Ping

AU - Lin, Kuan Hung

AU - Lin, Yu Chen

AU - Chou, Hsiu Chu

AU - Sheu, Joen Rong

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Hinokitiol (4-isopropyl-tropolone) is a bioactive compound with various pharmacological activities that is found in the wood of cupressaceous plants. Platelet activation plays an important role in thrombogenesis. In our previous study, hinokitiol specifically inhibited collagen-induced platelet aggregation ex vivo and prolonged thrombogenesis in vivo. The glycoprotein (GP) VI and integrin α2β1 are major collagen receptors that mediate platelet adhesion and aggregation. In our current study, we investigated which of these collagen receptors is involved in the hinokitiol-mediated inhibition of platelet activation. Treatment with 2-100 μM hinokitiol caused a dose-dependent right, parallel shift in the collagen concentration-response curve (0.5-10 μg/ml), with no change in the maximal responses. Furthermore, hinokitiol inhibited platelet aggregation and relative [Ca2+]i mobilization stimulated by convulxin, an agonist of GP VI, but not by aggretin, an agonist of integrin α2β1, indicating that hinokitiol mediates the inhibition of platelet activation through GP VI, rather than through integrin α2β1. Hinokitiol also specifically inhibited the convulxin-mediated activation of protein kinase C, phospholipase Cγ2, Akt, mitogen-activated protein kinases, and Lyn. Hinokitiol markedly diminished the co-immunoprecipitation of GP VI-bound Lyn after convulxin stimulation. In conclusion, hinokitiol, an antagonist of collagen GP VI may represent a novel antiplatelet drug for the prevention of thrombi associated with coronary and cerebral artery diseases.

AB - Hinokitiol (4-isopropyl-tropolone) is a bioactive compound with various pharmacological activities that is found in the wood of cupressaceous plants. Platelet activation plays an important role in thrombogenesis. In our previous study, hinokitiol specifically inhibited collagen-induced platelet aggregation ex vivo and prolonged thrombogenesis in vivo. The glycoprotein (GP) VI and integrin α2β1 are major collagen receptors that mediate platelet adhesion and aggregation. In our current study, we investigated which of these collagen receptors is involved in the hinokitiol-mediated inhibition of platelet activation. Treatment with 2-100 μM hinokitiol caused a dose-dependent right, parallel shift in the collagen concentration-response curve (0.5-10 μg/ml), with no change in the maximal responses. Furthermore, hinokitiol inhibited platelet aggregation and relative [Ca2+]i mobilization stimulated by convulxin, an agonist of GP VI, but not by aggretin, an agonist of integrin α2β1, indicating that hinokitiol mediates the inhibition of platelet activation through GP VI, rather than through integrin α2β1. Hinokitiol also specifically inhibited the convulxin-mediated activation of protein kinase C, phospholipase Cγ2, Akt, mitogen-activated protein kinases, and Lyn. Hinokitiol markedly diminished the co-immunoprecipitation of GP VI-bound Lyn after convulxin stimulation. In conclusion, hinokitiol, an antagonist of collagen GP VI may represent a novel antiplatelet drug for the prevention of thrombi associated with coronary and cerebral artery diseases.

KW - Collagen receptors

KW - Convulxin

KW - Glycoprotein VI

KW - Hinokitiol

KW - Platelet activation

UR - http://www.scopus.com/inward/record.url?scp=84908887308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908887308&partnerID=8YFLogxK

U2 - 10.3109/09537104.2013.863856

DO - 10.3109/09537104.2013.863856

M3 - Article

C2 - 24433214

AN - SCOPUS:84908887308

VL - 25

SP - 595

EP - 602

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 8

ER -